Welcome to our dedicated page for Evogene SEC filings (Ticker: EVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evogene Ltd. (EVGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Evogene files reports with the U.S. Securities and Exchange Commission, including Form 20‑F and recurring Form 6‑K reports that furnish financial statements, operating and financial reviews, and information on corporate actions.
For investors analyzing Evogene’s AI‑driven life‑science business, Form 6‑K submissions are particularly important. These filings often include press releases and slide presentations for quarterly results, unaudited condensed consolidated financial statements for interim periods, and operating and financial review and prospects documents. Through these materials, readers can examine revenue contributions from subsidiaries, cost‑reduction measures, restructuring steps, and transactions such as the sale of most of Lavie Bio’s activity and the transfer of the MicroBoost AI for Ag platform to ICL.
Evogene’s filings can also reference shareholder meeting outcomes, proxy materials, and incorporation by reference into registration statements on Form F‑3 and Form S‑8. Together, these documents outline the company’s capital markets activity, equity compensation plans and other corporate matters.
On Stock Titan, EVGN filings are updated as they are furnished to EDGAR, and AI‑powered tools summarize key points from lengthy documents. Users can quickly identify items such as interim financial trends, changes in subsidiary structure, or strategic shifts around tech‑engines like ChemPass AI, MicroBoost AI and GeneRator AI, without reading every page of the original filing.
Evogene Ltd. entered a warrant inducement agreement with an existing institutional investor, leading to the cash exercise of 3,384,616 existing warrants at a reduced exercise price of $1.00 per share for approximately $3.4 million in gross proceeds. In return, Evogene will issue 5,076,924 new Series A-1 and Series B-1 warrants with a $1.25 exercise price, five-year and 18‑month terms, and a 4.99% ownership cap. The company plans to use the net proceeds for working capital and general corporate purposes and will seek to register the resale of shares underlying the new warrants on a Form F‑3. Evogene agreed to short-term restrictions on issuing additional equity or entering variable rate transactions, with limited exceptions including a potential at‑the‑market program via its advisor, A.G.P./Alliance Global Partners.
Evogene Ltd. reports that its subsidiary Biomica has granted Shanghai Lishan Biopharmaceuticals an exclusive worldwide license for BMC128, a microbiome-based therapy designed to enhance anti-tumor immune activity in renal cell carcinoma and non-small cell lung cancer.
Lishan Biotech will lead global clinical development, manufacturing and commercialization of BMC128, which is completing a Phase 1 study and has shown an excellent safety profile with early signs of efficacy, including many patients with previously progressive disease achieving stable disease. Biomica is eligible for development and sales milestone payments and royalties on future commercial sales under the agreement.
Evogene Ltd. reports a planned change in its senior finance leadership. Chief Financial Officer Yaron Eldad will resign effective March 31, 2026, for personal reasons, and the company states there was no disagreement regarding its operations, policies, or practices. VP Finance Polina Ravzin, who has served in that role since 2022 and previously held finance positions at DSIT Solutions Ltd. and Acorn Energy Inc., will continue as VP Finance while also taking on CFO responsibilities.
Evogene Ltd. submitted a Form 6-K announcing that it has released its financial results for the third quarter ended September 30, 2025. The company also scheduled a conference call on November 20, 2025 to discuss these quarterly results and made an investor slide presentation available.
The third quarter 2025 financial results are provided in a press release attached as Exhibit 99.1, and the accompanying slide deck is attached as Exhibit 99.2. The GAAP financial statement tables in the press release are incorporated by reference into Evogene’s existing registration statements on Form F-3 and multiple Form S-8 filings, so they now form part of those registration materials from the date of this Form 6-K.
Evogene Ltd. furnished its unaudited condensed consolidated financial statements and an Operating and Financial Review and Prospects for the six-month period ended
Evogene Ltd. submitted a Form 6-K to provide investors with materials related to its second quarter 2025 results. The company states that it announced financial results for the quarter ended June 30, 2025, and furnished the full press release as an exhibit to this report.
Evogene also notes that it is holding a conference call on August 19, 2025 to discuss its quarterly results and has prepared a slide presentation for that call. Both the press release and the slide deck are attached as exhibits and incorporated by reference, and the GAAP financial statement tables in the press release are incorporated into certain existing Form F-3 and Form S-8 registration statements.
Evogene Ltd. reports that its shareholders approved all proposals presented at its annual general meeting of shareholders held on August 18, 2025, following a one‑week adjournment from the original meeting date. The proposals were described in the proxy statement furnished to the SEC on June 17, 2025. The information in this Form 6‑K is incorporated by reference into Evogene’s existing registration statements on Form F‑3 and several Form S‑8 filings, meaning it now forms part of those registration documents unless later superseded.
Evogene Ltd. reported that its Annual General Meeting of Shareholders, originally convened on August 11, 2025, was adjourned for one week due to a lack of quorum, meaning not enough shares were represented to hold a valid meeting. The meeting is scheduled to be reconvened on Monday, August 18, 2025 at 3:00 p.m. (Israel time) at the company’s executive offices in Rehovot, Israel.
The report also states that its content is incorporated by reference into Evogene’s existing registration statements on Form F-3 and multiple Form S-8 filings, so this update becomes part of those documents for U.S. securities law purposes.
FAQ
What is the current stock price of Evogene (EVGN)?
What is the market cap of Evogene (EVGN)?
